[go: up one dir, main page]

AR113036A1 - Conjugado de iduronato-2-sulfatasa - Google Patents

Conjugado de iduronato-2-sulfatasa

Info

Publication number
AR113036A1
AR113036A1 ARP180102143A ARP180102143A AR113036A1 AR 113036 A1 AR113036 A1 AR 113036A1 AR P180102143 A ARP180102143 A AR P180102143A AR P180102143 A ARP180102143 A AR P180102143A AR 113036 A1 AR113036 A1 AR 113036A1
Authority
AR
Argentina
Prior art keywords
iduronate
conjugate
immunoglobulin
same
sulfatase
Prior art date
Application number
ARP180102143A
Other languages
English (en)
Inventor
Se Chang Kwon
Sung Youb Jung
Jung Kuk Kim
Dae Jin Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR113036A1 publication Critical patent/AR113036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un conjugado en el que una región Fc de inmunoglobulina está unida a una enzima iduronato-2-sulfatasa a través de un resto de enlace polimérico no peptídico. Además, se proporciona un conjugado, un método para preparar el mismo, y una composición que incluye el mismo en el que un resto de enlace de polímero no peptídico está específicamente unido a una inmunoglobulina Fc.
ARP180102143A 2017-07-28 2018-07-30 Conjugado de iduronato-2-sulfatasa AR113036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170096470 2017-07-28

Publications (1)

Publication Number Publication Date
AR113036A1 true AR113036A1 (es) 2020-01-22

Family

ID=65040773

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102143A AR113036A1 (es) 2017-07-28 2018-07-30 Conjugado de iduronato-2-sulfatasa

Country Status (6)

Country Link
US (1) US20200230253A1 (es)
JP (1) JP2020528756A (es)
KR (1) KR20190013615A (es)
AR (1) AR113036A1 (es)
TW (1) TW201920664A (es)
WO (1) WO2019022563A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
MA71657A (fr) * 2019-04-03 2025-05-30 Denali Therapeutics Inc. Formulations de molécules protéiques comprenant de l'iduronate 2-sulfatase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR20210130260A (ko) * 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
KR20180127319A (ko) * 2016-01-15 2018-11-28 상가모 테라퓨틱스, 인코포레이티드 신경 질환의 치료를 위한 방법 및 조성물

Also Published As

Publication number Publication date
TW201920664A (zh) 2019-06-01
US20200230253A1 (en) 2020-07-23
WO2019022563A3 (ko) 2019-04-11
JP2020528756A (ja) 2020-10-01
WO2019022563A2 (ko) 2019-01-31
KR20190013615A (ko) 2019-02-11

Similar Documents

Publication Publication Date Title
AR120515A2 (es) Conjugado de enzimas terapéuticas
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CO2019009365A2 (es) Anticuerpos anti-lag3
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
EP3484499A4 (en) TGFB ANTIBODIES, METHODS AND USE
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
EP3873512A4 (en) EPCAM ANTIBODIES, ACTIVABLE ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF
MX377710B (es) Anticuerpos monoclonales contra bcma.
MX2017013613A (es) Neoepitodos de cancer.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201700546A1 (ru) Композит полипропилен - углеродное волокно
EA201700547A1 (ru) Армированная волокнами полимерная композиция
UY36759A (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
EA201690492A1 (ru) Проникающие в клетку конъюгаты и способы их применения
CR20190417A (es) Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas
ECSP12012105A (es) Antídotos de Anticoagulantes
CO2018013314A2 (es) Inmunglobulinas conjugadas con lisina
MX2020002611A (es) Activador especifico de akt3 y usos del mismo.
EP3426297A4 (en) GITR ANTIBODIES, METHODS AND USES
MX2019003570A (es) Agentes de union monoclonales de cmet, conjugados de farmaco de los mismos y usos de los mismos.
MX2024003463A (es) Anticuerpos anti-edb y conjugados anticuerpo-farmaco.
CO2017001384A2 (es) Anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon
MX2019010895A (es) Formulacion liquida de anticuerpo anti-tnf alfa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal